Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$22.19 USD
+0.21 (0.96%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.21 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLDX 22.19 +0.21(0.96%)
Will CLDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLDX
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last?
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates
Other News for CLDX
Interesting CLDX Put And Call Options For September 19th
RBC downgrades Jasper Therapeutics on questions about briquilimab
Celldex Therapeutics’ Promising Phase 2 Study on Eosinophilic Esophagitis
Celldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
Celldex Therapeutics Advances Phase 2 Study on Barzolvolimab for Prurigo Nodularis